Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Theranostic imaging of lymphoma using radiolabelled αCD19-antibodies

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 3742

Dr Dominik Sonanini - Tübingen University Hospital, Tübingen, Germany

Dr Sonanini speaks with ecancer at AACR 2018 about using a radiolabeled CD-19 antibody to determine patient eligibility for targeted therapies and monitor responses.

He outlines the facilities developed at the University of Tübingen to monitor and proceed with patients currently participating in trials, and discusses the increasing utility of imaging in oncology.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation